The United Kingdom and the United States have forged a major bilateral deal that will preserve no duties on British pharmaceutical products going into the American market.
The Terms of the Deal
As part of the deal, the UK has pledged to boost expenditure on drugs through the public health system. This move ensures that import taxes on these crucial exports will remain at zero for a duration of 36 months.
This development follows previous warnings to dramatically increase import taxes on patented pharmaceutical imports, with increases floated reaching double the cost.
"This agreement with the United Kingdom strengthens the international landscape for cutting-edge drugs and introduces much-needed equity to U.S.–U.K. medicine commerce," an announcement said.
Commercial Significance
Pharmaceuticals are one of the UK's most significant exports to the America, which is by far the largest market for large companies like GSK and AstraZeneca.
Statistics show that in the 12 months prior to last September, the UK sold medicines valued at over eleven billion pounds to the US. This figure accounted for a significant portion of all goods exports in that span.
"This guarantee protects jobs, increases investment and paves the way for the UK to emerge as a international leader for biotech and pharma," a government official remarked.
Key UK Commitments
The deal involves several specific pledges from the British government:
- Price Threshold Increase: The UK will raise the cost ceiling at which it judges new medicines to be unaffordable by a quarter.
- Higher Drug Budget: There is a target to increase total NHS spending on drugs from 0.3 percent of GDP to 0.6 percent over the coming ten years.
- Refund Ceiling: The sum drug companies must pay back to the NHS to stay within budget will be restricted at 15%. In the past, repayments exceeded 20%.
Broader Context
The deal comes amid a protracted dispute between the sector and the British authorities over drug pricing and approval rates.
This friction were intensified by assertions that American consumers were paying a premium for the identical medicines than consumers in the Britain and the EU.
Recently, several major drug company projects in the UK have been delayed or cancelled, while major investments have been announced toward projects in the United States.
The Science Minister stated that the NHS needed to invest a greater share on drugs, noting that its expenditure on drugs had shrunk as a proportion of its resources over the previous ten-year period.
